Bibliometric and visual analysis of postmenopausal osteoporosis based on highly cited SCI papers

doi:10.12307/2024.803

Abstract

Abstract: BACKGROUND: Bibliometrics and visual analyses based on thematic literature are particularly important for understanding the foundation and frontiers of postmenopausal osteoporosis research.
OBJECTIVE: To perform bibliometric, citation, and visualization analyses of highly cited SCI papers in postmenopausal osteoporosis research over the last 20 years.
METHODS: The top 100 highly cited papers on postmenopausal osteoporosis published between 2003 and 2022 included in SCI-EXPANDED catalog of the Web of Science database were obtained for bibliometric measure and visual analysis using CiteSpace software.
RESULTS AND CONCLUSION: The top 100 highly cited papers have a total of 67 377 citations in the Web of Science Core Collection, with an annual average of 49.17 citations per paper. Postmenopausal osteoporosis research primarily involves medical, engineering, biological, and multidisciplinary fields. The subcategories are dominated by endocrinology and metabolism, and medicine: internal medicine. Stable and close cooperative network relationships have been formed globally. United States, University of California System, Cummings, and Steven R are the country, research institution, and author, respectively, with the most highly-cited publications. The frontiers of postmenopausal osteoporosis research mainly include calcium and vitamin D supplementation and fracture risk, clinical studies of bisphosphonates in the treatment of postmenopausal osteoporosis, atypical femur fracture, clinical studies of new drugs and sequential treatment of postmenopausal osteoporosis, predictors of fracture risk, mid- and long-term follow-up of osteoporotic vertebral compression fractures, genetic polymorphisms and hereditary factors, formulation and updating of clinical practice guidelines for postmenopausal osteoporosis. Large cohort studies, high-quality randomized controlled trials, systematic reviews, meta-analyses, and clinical practice guidelines are the great engines that drive the development of clinical research in postmenopausal osteoporosis. We should make efforts in the above areas to improve China’s international influence in the field of osteoporosis.

Key words: postmenopausal osteoporosis, highly cited paper, Web of Science, WoS, bibliometrics, CiteSpace, visualization, knowledge mapping, sequential therapy, osteoporotic vertebral compression fracture

CLC Number:

Li Yan, Liu Ning, Wang Xiaoyang, Xiao Xiangyu, Liu Ping, Zhang Yili, Jiang Hongjiang, Zhu Liguo, Wei Xu. Bibliometric and visual analysis of postmenopausal osteoporosis based on highly cited SCI papers[J]. Chinese Journal of Tissue Engineering Research, 2024, 28(35): 5681-5687.

Figures/Tables 11

References

[1] 中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊疗指南(2022)[J].中华骨质疏松和骨矿盐疾病杂志,2022,15(6):573-611.
[2] 魏戌,刘宁,章轶立,等.骨质疏松症的共病研究与早期筛查[J].中国全科医学,2022,25(35):4369-4374.
[3] 肖姚,刘颖,吴惠一,等.绝经后骨质疏松症临床实践指南和专家共识的质量评价[J].现代预防医学,2023,50(8):1516-1523.
[4] AYERS C, KANSAGARA D, LAZUR B, et al. Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians. Ann Intern Med. 2023;176(2):182-195.
[5] 李杰,陈超美. CiteSpace:科技文本挖掘及可视化[M].北京:首都经济贸易大学出版社,2017.
[6] SYNNESTVEDT MB, CHEN C, HOLMES JH. CiteSpace II: visualization and knowledge discovery in bibliographic databases. AMIA Annu Symp Proc. 2005;2005:724-728.
[7] 李绍烁,顾一丹,邵阳,等.CiteSpace知识图谱可视化分析中医药防治绝经后骨质疏松症[J].中国组织工程研究,2020,24(26):4224-4230.
[8] QIU Y, YANG W, WANG Q, et al. Osteoporosis in postmenopausal women in this decade: a bibliometric assessment of current research and future hotspots. Arch Osteoporos. 2018;13(1):121.
[9] ZHOU S, TAO Z, ZHU Y, et al. Mapping theme trends and recognizing hot spots in postmenopausal osteoporosis research: a bibliometric analysis. PeerJ. 2019;7:e8145.
[10] ZILELI M, FORNARI M, COSTA F, et al. Epidemiology, natural course, and preventive measures of osteoporotic vertebral fractures: WFNS Spine Committee Recommendations. J Neurosurg Sci. 2022;66(4):282-290.
[11] JACKSON RD, LACROIX AZ, GASS M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354(7): 669-683.
[12] LIU C, KUANG X, LI K, et al. Effects of combined calcium and vitamin D supplementation on osteoporosis in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. Food Funct. 2020;11(12):10817-10827.
[13] HEIDARI B, HAJIAN-TILAKI K, BABAEI M. Effectiveness and safety of routine calcium supplementation in postmenopausal women. A narrative review. Diabetes Metab Syndr. 2020;14(4):435-442.
[14] CUI Y, CAI H, GAO Y, et al. Associations of dietary intakes of calcium, magnesium and soy isoflavones with osteoporotic fracture risk in postmenopausal women: a prospective study. J Nutr Sci. 2022;11:e62.
[15] LONG G, LIU C, LIANG T, et al. Predictors of osteoporotic fracture in postmenopausal women: a meta-analysis. J Orthop Surg Res. 2023;18(1):574.
[16] REIS AR, SANTOS RKF, DOS SANTOS CB, et al. Supplementation of vitamin D isolated or calcium-associated with bone remodeling and fracture risk in postmenopausal women without osteoporosis: A systematic review of randomized clinical trials. Nutrition. 2023;116:112151.
[17] CHEVALLEY T, BRANDI ML, CASHMAN KD, et al. Role of vitamin D supplementation in the management of musculoskeletal diseases: update from an European Society of Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) working group. Aging Clin Exp Res. 2022;34(11):2603-2623.
[18] BONE HG, HOSKING D, DEVOGELAER JP, et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350(12):1189-1199.
[19] BLACK DM, GREENSPAN SL, ENSRUD KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003;349(13):1207-1215.
[20] LEBOFF MS, GREENSPAN SL, INSOGNA KL, et al. The clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022;33(10): 2049-2102.
[21] SHANE E, BURR D, EBELING PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American
Society for Bone and Mineral Research. J Bone Miner Res. 2010;25(11): 2267-2294.
[22] SHANE E, BURR D, ABRAHAMSEN B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1-23.
[23] LO JC, GRIMSRUD CD, OTT SM, et al. Atypical femur fracture incidence in women increases with duration of bisphosphonate exposure. Osteoporos Int. 2019;30(12):2515-2520.
[24] BLACK DM, GEIGER EJ, EASTELL R, et al. Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. N Engl J Med. 2020;383(8):743-753.
[25] MILLER PD, BOLOGNESE MA, LEWIECKI EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43(2):222-229.
[26] CUMMINGS SR, FERRARI S, EASTELL R, et al. Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. J Bone Miner Res. 2018;33(2):190-198.
[27] 李梅,章振林,夏维波.骨质疏松症药物治疗的必由之路：长程序贯治疗[J].中华骨质疏松和骨矿盐疾病杂志,2021,14(5):441-446.
[28] EASTELL R, NICKELSEN T, MARIN F, et al. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res. 2009;24(4):726-736.
[29] KOBAYAKAWA T, MIYAZAKI A, TAKAHASHI J, et al. Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: The prospective VICTOR study. Bone. 2022;162:116480.
[30] RAMCHAND SK, LEDER BZ. Sequential Therapy for the Long-Term Treatment of Postmenopausal Osteoporosis. J Clin Endocrinol Metab. 2023:dgad496.
[31] JOHNELL O, KANIS JA, ODEN A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005;20(7):1185-1194.
[32] COMPSTON JE, WYMAN A, FITZGERALD G, et al. Increase in Fracture Risk Following Unintentional Weight Loss in Postmenopausal Women: The Global Longitudinal Study of Osteoporosis in Women. J Bone Miner Res. 2016;31(7):1466-1472.
[33] COMPSTON JE, WATTS NB, CHAPURLAT R, et al. Obesity is not protective against fracture in postmenopausal women: GLOW. Am J Med. 2011; 124(11):1043-1050.
[34] LITWIC AE, WESTBURY LD, WARD K, et al. Adiposity and bone microarchitecture in the GLOW study. Osteoporos Int. 2021;32(4):689-698.
[35] LI G, COMPSTON JE, LESLIE WD, et al. Relationship Between Obesity and Risk of Major Osteoporotic Fracture in Postmenopausal Women: Taking Frailty Into Consideration. J Bone Miner Res. 2020;35(12):2355-2362.
[36] BARRON RL, OSTER G, GRAUER A, et al. Determinants of imminent fracture risk in postmenopausal women with osteoporosis. Osteoporos Int. 2020;31(11):2103-2111.
[37] 张晓敏,刘师伟,董进,等.生殖因素对绝经后骨质疏松性椎体压缩性骨折的影响[J].中华骨质疏松和骨矿盐疾病杂志,2023,16(3):236-242.
[38] 林靖,阿斯楞,冬梅.内蒙古地区绝经后女性骨密度、骨骼肌与骨折风险性的关系[J].中国组织工程研究,2022,26(14):2133-2137.
[39] WANG X, ZHANG Y, QI B, et al. IL-6 and Leptin Are Potential Biomarkers for Osteoporotic Fracture Risk Assessment and Prediction of Postmenopausal Women with Low Bone Mass: A Follow-Up Study Using a Regional Sample Cohort. Oxid Med Cell Longev. 2022;2022:8691830.
[40] BLIUC D, NGUYEN ND, NGUYEN TV, et al. Compound risk of high mortality following osteoporotic fracture and refracture in elderly women and men. J Bone Miner Res. 2013;28(11):2317-2324.
[41] TAKAHASHI S, TERAI H, HOSHINO M, et al. Risk factors of the poor long-term prognosis of osteoporotic vertebral fractures: A multicenter cohort study. J Orthop Surg (Hong Kong). 2021;29(1):2309499021994969.
[42] MORIN SN, YAN L, LIX LM, et al. Long-term risk of subsequent major osteoporotic fracture and hip fracture in men and women: a population-based observational study with a 25-year follow-up. Osteoporos Int. 2021; 32(12):2525-2532.
[43] 中国康复医学会骨质疏松预防与康复专业委员会.骨质疏松性椎体压缩骨折诊治专家共识(2021版)[J].中华医学杂志,2021,101(41): 3371-3379.
[44] MINAMIDE A, MAEDA T, YAMADA H, et al. Early versus delayed kyphoplasty for thoracolumbar osteoporotic vertebral fractures: The effect of timing on clinical and radiographic outcomes and subsequent compression fractures. Clin Neurol Neurosurg. 2018;173:176-181.
[45] INOSE H, KATO T, SHIRASAWA S, et al. Time Course of Acute Vertebral Fractures: A Prospective Multicenter Cohort Study. J Clin Med. 2021;10(24): 5961.
[46] MASALA S, MAMMUCARI M, ANGELOPOULOS G, et al. Percutaneous vertebroplasty in the management of vertebral osteoporotic fractures. Short-term, mid-term and long-term follow-up of 285 patients. Skeletal Radiol. 2009;38(9):863-869.
[47] ANSELMETTI GC, MANCA A, HIRSCH J, et al. Percutaneous vertebroplasty in osteoporotic patients: an institutional experience of 1,634 patients with long-term follow-up. J Vasc Interv Radiol. 2011;22(12):1714-1720.
[48] JOYCE DM, GRANVILLE M, BERTI A, et al. Vertebral Augmentation Compared to Conservative Treatment of Vertebra Plana and High-Degree Osteoporotic Vertebral Fractures: A Review of 110 Fractures in 100 Patients. Cureus. 2022;14(2):e22006.
[49] KUO YR, CHENG TA, CHOU PH, et al. Healing of Vertebral Compression Fractures in the Elderly after Percutaneous Vertebroplasty-An Analysis of New Bone Formation and Sagittal Alignment in a 3-Year Follow-Up. J Clin Med. 2022;11(3):708.
[50] LI Q, LONG X, WANG Y, et al. Clinical observation of two bone cement distribution modes after percutaneous vertebroplasty for osteoporotic vertebral compression fractures. BMC Musculoskelet Disord. 2021;22(1): 577.
[51] TAN L, WEN B, GUO Z, et al. The effect of bone cement distribution on the outcome of percutaneous Vertebroplasty: a case cohort study. BMC Musculoskelet Disord. 2020;21(1):541.
[52] SAHINTURK F, SONMEZ E, AYHAN S, et al. The Influence of Percutaneous Vertebral Augmentation Techniques on Recompression in Patients with Osteoporotic Vertebral Compression Fractures. Percutaneous Vertebroplasty versus Balloon Kyphoplasty. World Neurosurg. 2023;176:e447-e455.
[53] 杨策凯,蔡卓延,陈明,等.绝经后女性椎旁肌退化与经皮穿刺椎体成形后再骨折的相关性[J].中国组织工程研究,2024,28(9):1414-1419.
[54] JIN J, SHEN W. Long-term therapeutic effect of percutaneous kyphoplasty combined with & without back muscle rehabilitation exercise in elderly patients. A comparative study. Pak J Med Sci. 2022;38(6):1595-1600.
[55] HUNTOON EA, SCHMIDT CK, SINAKI M. Significantly fewer refractures after vertebroplasty in patients who engage in back-extensor-strengthening exercises. Mayo Clin Proc. 2008;83(1):54-57.
[56] STYRKARSDOTTIR U, HALLDORSSON BV, GRETARSDOTTIR S, et al. Multiple genetic loci for bone mineral density and fractures. N Engl J Med. 2008; 358(22):2355-2365.
[57] BUCH-LARSEN K, JØRGENSEN NR, JENSEN LT, et al. Denosumab vs. zoledronic acid treatment in post-menopausal breast cancer: a 2-year prospective observational study. Scand J Clin Lab Invest. 2021;81(6):425-431.
[58] ROATO I, PAVONE L, PEDRAZA R, et al. Denosumab and Zoledronic Acid Differently Affect Circulating Immune Subsets: A Possible Role in the Onset of MRONJ. Cells. 2023;12(20):2430.